Azadeh Abravan

Oct 21, 2024 | nature.com | Azadeh Abravan

Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-024-02838-w, published online 04 September 2024In Fig. 5 of this article, the first age range was originally listed as ‘40–40’ rather than ‘40–49’; the figure should have appeared as shown below. The original article has been updated.

Sep 4, 2024 | nature.com | Azadeh Abravan

AbstractComorbidities have been shown to impact the presentation and treatment of patients with cancers. This study investigates the prevalence and patterns of comorbidity in a pan-cancer cohort of patients treated at a large UK specialist cancer center over a 9-year period.

Jun 16, 2023 | redjournal.org | Eliana Vasquez Osorio |Azadeh Abravan |Andrew Green |Marcel Van Herk

Purpose Dysphagia is a common toxicity after head and neck (HN) radiotherapy that negatively affects quality of life. We explored the relationship between radiotherapy dose to normal HN structures and dysphagia one year after treatment using image-based datamining (IBDM), a voxel-based analysis technique. Materials and Methods We used data from 104 oropharyngeal cancer patients treated with definitive (Chemo)RT.

May 12, 2023 | estro.org | Corinne Faivre-Finn |Azadeh Abravan

Results Of 2,131 patients analyzed, 202 (9.5%, range 2.0-16.5%) developed acute G3+ esophageal toxicity (Table 1).  There was a strong correlation between esophageal mean dose and V35Gy (90%, range 83-96%). As the CONVERT trial did not collect mean esophageal dose, V35Gy was selected for analyses of all 5 studies. On multivariable analysis, acute G3+ esophageal toxicity was associated with concurrent chemotherapy (OR=2.9, p=0.03) and esophageal V35Gy (OR=1.02, p<0.0001).